Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Metabolic medicine · Methylmalonic Acidemia with Homocystinuria, cblC Type

Long-Term Health: Monitoring Your Eyes, Heart, and Brain

At a Glance

MMA-HCU can affect the eyes, kidneys, heart, lungs, and brain over time, even when MMA and homocysteine blood levels are controlled. Regular, individualized monitoring helps detect retinal, kidney, heart, neurological, and psychiatric complications early.

While the daily management of Methylmalonic Acidemia with Homocystinuria (MMA-HCU) focuses on blood levels, the condition can affect multiple organ systems over time. Because the cblC defect impacts how every cell in the body functions, it requires long-term monitoring of the eyes, kidneys, heart, and brain [1][2]. Importantly, a normal current homocysteine or MMA result does not guarantee the absence of complications, reinforcing the need for ongoing clinical surveillance.

Protecting Your Vision

One of the most unique and challenging aspects of the cblC defect is its impact on the eyes, specifically the retina (the light-sensitive layer at the back of the eye).

In the early-onset form of the disease, a condition called maculopathy or retinal degeneration can begin very early, sometimes within the first few months of life [3][4]. This often shows up as “bull’s-eye” thinning in the center of the retina. Crucially, this eye damage can sometimes progress even when blood levels of MMA and homocysteine are well-controlled [3][5]. Regular exams with an ophthalmologist are essential and may include specialized tests depending on age, symptoms, and cooperation:

  • Optical Coherence Tomography (OCT): A non-invasive imaging test that looks at the thickness of retinal layers [6].
  • Electroretinography (ERG): A test that measures the electrical response of the eye’s light-sensitive cells [7].
    While early therapy may slow progression, some retinal injury may be irreversible.

Kidney Health

The kidneys are also at risk, primarily from a condition called Thrombotic Microangiopathy (TMA). This occurs when tiny blood clots form in the small blood vessels of the kidney, leading to inflammation and potential kidney failure [1].

If kidney function declines, a patient might experience high blood pressure, swelling, or even require dialysis [1][8]. Evaluating for TMA requires a broad clinician-directed approach checking a CBC, platelets, a blood smear, bilirubin, LDH, creatinine, blood pressure, and urine protein. The good news is that rapid, high-dose treatment with hydroxocobalamin (B12) can often improve this damage. In some reported cases, patients were able to stop dialysis once their metabolic levels stabilized, though some kidney injury may be permanent [1].

Heart and Lung Considerations

A serious but often treatable complication is Pulmonary Hypertension (PH), which is high blood pressure in the arteries of the lungs. This forces the right side of the heart to work harder, which can lead to heart failure if left untreated [9][10].

Signs to watch for include sudden shortness of breath, turning blue around the lips (cyanosis), or extreme fatigue during play or exercise [10]. While PH can be life-threatening, research shows that it may improve significantly once proper metabolic treatment and targeted heart medications are started [11]. BNP (a marker of cardiac strain) and echocardiography are risk- and symptom-dependent surveillance tools, rather than automatically required screening tests for every patient at all times.

Neurological and Psychiatric Impact

The impact on the brain often depends on when the condition first appeared:

  • Early-Onset (Infants): The focus is often on developmental milestones. Challenges can include hypotonia (low muscle tone), seizures, or delays in walking and talking [12][13]. Early and consistent treatment is the best way to support healthy brain development [14].
  • Late-Onset (Teens and Adults): The impact is often more subtle and can be mistaken for other conditions. Common issues include neuropathy (numbness or weakness in the legs), “brain fog,” or sudden psychiatric changes like severe anxiety, mood swings, or even psychosis (losing touch with reality) [15][2][16].

The encouraging reality is that many of these neurological and psychiatric symptoms may improve substantially once treatment begins [17][18]. However, because some injury may be irreversible and require separate organ or psychiatric support, regular check-ins with your metabolic team are the best way to catch and treat issues early.

Common questions in this guide

Can MMA-HCU cause organ problems even when blood tests are normal?
Yes. In MMA-HCU, complications involving the eyes, kidneys, heart, lungs, or brain can develop or continue even when MMA and homocysteine levels are controlled. Regular, individualized follow-up helps clinicians find problems early.
Which eye tests are used to monitor MMA-HCU?
An ophthalmologist may use optical coherence tomography, or OCT, to create images of the retinal layers and electroretinography, or ERG, to measure electrical responses from light-sensitive eye cells. The testing schedule depends on age, symptoms, and the person’s ability to complete the exam. Early treatment may slow retinal damage, but some injury can be permanent.
How is kidney injury from MMA-HCU evaluated?
Kidney injury from thrombotic microangiopathy, or TMA, may cause high blood pressure, swelling, reduced kidney function, or a need for dialysis. Clinicians may check blood counts and platelets, a blood smear, bilirubin, LDH, creatinine, blood pressure, and urine protein. Rapid hydroxocobalamin treatment can improve some cases, although kidney damage may remain.
What symptoms can suggest pulmonary hypertension in MMA-HCU?
Pulmonary hypertension is high blood pressure in the arteries of the lungs and can strain the right side of the heart. Warning signs include sudden shortness of breath, blue lips, or unusual fatigue during play or exercise. A clinician may use BNP, a marker of heart strain, and echocardiography based on symptoms and risk rather than as automatic tests for everyone.
What brain or mental health changes can MMA-HCU cause?
Early-onset MMA-HCU may be associated with low muscle tone, seizures, and delays in walking or talking, while later-onset disease may cause numbness or weakness, brain fog, anxiety, mood changes, or psychosis. Many symptoms can improve after treatment, but some injury may be permanent. Neurology or psychiatry can work with the metabolic team when these changes occur.

Get notified when new evidence is published on Methylmalonic acidemia with homocystinuria.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.

    Beck BB, van Spronsen F, Diepstra A, et al.

    Pediatric nephrology (Berlin, Germany) 2017; (32(5)):733-741 doi:10.1007/s00467-016-3399-0.

    PMID: 27289364
  2. 2

    Late-onset cblC deficiency around puberty: a retrospective study of the clinical characteristics, diagnosis, and treatment.

    Chen Z, Dong H, Liu Y, et al.

    Orphanet journal of rare diseases 2022; (17(1)):330 doi:10.1186/s13023-022-02471-x.

    PMID: 36056359
  3. 3

    Retinal Changes in Early-Onset cblC Methylmalonic Acidemia Identified Through Expanded Newborn Screening: Highlights from a Case Study and Literature Review.

    Michieletto P, Baldo F, Madonia M, et al.

    Genes 2025; (16(6)) doi:10.3390/genes16060635.

    PMID: 40565527
  4. 4

    Ocular disease in the cobalamin C defect: a review of the literature and a suggested framework for clinical surveillance.

    Weisfeld-Adams JD, McCourt EA, Diaz GA, Oliver SC

    Molecular genetics and metabolism 2015; (114(4)):537-46.

    PMID: 25742969
  5. 5

    Ophthalmic Manifestations and Long-Term Visual Outcomes in Patients with Cobalamin C Deficiency.

    Brooks BP, Thompson AH, Sloan JL, et al.

    Ophthalmology 2016; (123(3)):571-82.

    PMID: 26825575
  6. 6

    Optical coherence tomography morphology and evolution in cblC disease-related maculopathy in a case series of very young patients.

    Bacci GM, Donati MA, Pasquini E, et al.

    Acta ophthalmologica 2017; (95(8)):e776-e782 doi:10.1111/aos.13441.

    PMID: 28481040
  7. 7

    Cobalamin C Deficiency Shows a Rapidly Progressing Maculopathy With Severe Photoreceptor and Ganglion Cell Loss.

    Bonafede L, Ficicioglu CH, Serrano L, et al.

    Investigative ophthalmology & visual science 2015; (56(13)):7875-87 doi:10.1167/iovs.15-17857.

    PMID: 26658511
  8. 8

    Cobalamin c deficiency associated with antifactor h antibody-associated hemolytic uremic syndrome in a young adult.

    Philipponnet C, Desenclos J, Brailova M, et al.

    BMC nephrology 2020; (21(1)):96 doi:10.1186/s12882-020-01748-2.

    PMID: 32164588
  9. 9

    Long-term outcome of CblC deficiency complicated with pulmonary hypertension.

    Ding S, Deng Y, Hao L, et al.

    Orphanet journal of rare diseases 2025; (20(1)):276 doi:10.1186/s13023-025-03839-5.

    PMID: 40468431
  10. 10

    Pulmonary hypertension in late-onset Methylmalonic Aciduria and Homocystinemia: a case report.

    Wen LY, Guo YK, Shi XQ

    BMC pediatrics 2020; (20(1)):243 doi:10.1186/s12887-020-02130-9.

    PMID: 32443968
  11. 11

    Reversible Pulmonary Hypertension in CblC Deficiency (MMACHC c.80 A>G): long-term outcomes of metabolic and PH-targeted therapy.

    He R, Liu J, Tang X, et al.

    Pediatric research 2026; (100(2)):776-781 doi:10.1038/s41390-025-04720-8.

    PMID: 41454146
  12. 12

    The Follow-Up of Chinese Patients in cblC Type Methylmalonic Acidemia Identified Through Expanded Newborn Screening.

    Ling S, Wu S, Shuai R, et al.

    Frontiers in genetics 2022; (13()):805599 doi:10.3389/fgene.2022.805599.

    PMID: 35242167
  13. 13

    Early neurodevelopmental characterization in children with cobalamin C/defect.

    Ricci D, Martinelli D, Ferrantini G, et al.

    Journal of inherited metabolic disease 2020; (43(2)):367-374 doi:10.1002/jimd.12171.

    PMID: 31503356
  14. 14

    Outcomes of patients with cobalamin C deficiency: A single center experience.

    Bourque DK, Mellin-Sanchez LE, Bullivant G, et al.

    JIMD reports 2021; (57(1)):102-114 doi:10.1002/jmd2.12179.

    PMID: 33473346
  15. 15

    Late-onset methylmalonic acidemia and homocysteinemia (cblC disease): systematic review.

    Arhip L, Brox-Torrecilla N, Romero I, et al.

    Orphanet journal of rare diseases 2024; (19(1)):20 doi:10.1186/s13023-024-03021-3.

    PMID: 38245797
  16. 16

    Distinct clinical, neuroimaging and genetic profiles of late-onset cobalamin C defects (cb1C): a report of 16 Chinese cases.

    Wang X, Yang Y, Li X, et al.

    Orphanet journal of rare diseases 2019; (14(1)):109 doi:10.1186/s13023-019-1058-9.

    PMID: 31092259
  17. 17

    High-dose hydroxocobalamin achieves biochemical correction and improvement of neuropsychiatric deficits in adults with late onset cobalamin C deficiency.

    Higashimoto T, Kim AY, Ogawa JT, et al.

    JIMD reports 2020; (51(1)):17-24 doi:10.1002/jmd2.12087.

    PMID: 32071835
  18. 18

    Late-onset cobalamin C defect with a rare MMACHC c.457 C > T variant: a case report and literature review.

    Huang Q, Liao Z, Li H, et al.

    BMC pediatrics 2026; (26(1)).

    PMID: 42897485

This page explains long-term organ monitoring for MMA-HCU for educational purposes only and does not replace medical advice. Ask your metabolic team how to tailor eye, kidney, heart, and neurological follow-up to your or your child’s needs.